A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 47-53

  Liu, Fei ^a   Luo, Limei ^a   Wei, Yonggang ^a   Wang, Wentao ^a   Li, Bo ^a   Yan, Lvnan ^a   Wen, Tianfu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Case control study; Hepatocellular carcinoma; NQO1 polymorphism; Susceptibility

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGE DISTRIBUTION; ALLELE; ANTIGEN DETECTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DNA MODIFICATION; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NQO1 GENE; NUCLEIC ACID BASE SUBSTITUTION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 84872762402     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0509-x     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev. 2006;6:674-87.
3. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346-53.
4. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-43.
5. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-63.
6. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002;36:1046-9.
7. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol. 2002;35(5 Suppl2):S79-85.
8. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946-52.
9. Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846-53.
10. Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10-5.
11. Joseph P, Long DJ, Klein-Szanto AJ, Jaiswal AK. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol. 2000;60:207-14.
12. Iskander K, Jaiswal AK. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact. 2005;153-154:147-57.
13. Siegel D, Gustafson DL, Dehn DL, et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol. 2004;65:1238-47.
14. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys. 2010;501:116-23.
15. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 2005;19:316-21.
16. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A. 2002;99:3099-104.
17. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A. 2002;99:13125-30.
18. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res. 2004;555:149-71.
19. Rauth AM, Goldberg Z, Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res. 1997;9:339-49.
20. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199-206.
21. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;5:69-75.
22. Siegel D, McGuinness SM, Winski, et al. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113-21.
23. Misra V, Grondin A, Klamut HJ, et al. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998-1002.
24. Kuehl BL, Paterson JW, Peacock JW, et al. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995;72:555-61.
25. Zhang JH, Li Y, Wang R, et al. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol. 2003;9:1390-3.
26. van der Logt EM, Bergevoet SM, Roelofs HM, et al. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colon cancer. Mutat Res. 2006;593:39-49.
27. Menzel HJ, Sarmanova J, Soucek P, et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer. 2004;90:1989-94.
28. Schulz WA, Krummeck A, Rosinger I, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235-9.
29. Long 2nd DJ, Waikel RL, Wang XJ, et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 2000;60:5913-5.
30. Long 2nd DJ, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a] -anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst. 2001;93:1166-70.
31. Akkiz H, Bayram S, Bekar A, et al. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev. 2010;11:1051-8.
32. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-87.
33. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
34. Nebert DW, Roe AL, Vandale SE, et al. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med. 2002;4:62-70.
35. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis Bvirus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002;62:3939-44.
36. Asher G, Lotem J, Cohen B, et al. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2001;98:1188-93.
37. Gong X, Kole L, Iskander K, et al. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 2007;67:5380-8.
38. Long 2nd DJ, Gaikwad A, Multani A, et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res. 2002;62:3030-6.
39. Hamajima N, Matsuo K, Iwata H, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7:103-8.
40. Begleiter A, Norman A, Leitao D, et al. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol. 2005;41:927-33.
41. Soucek P, Sarmanova J, Kristensen VN, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Int Arch Occup Environ Health. 2002;75:S86-92.
42. Kiyohara C, Yoshimasu K, Takayama K, et al. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med. 2005;7:463-78.
43. Sarbia M, Bitzer M, Siegel D, et al. Association between NAD(P)H: quinoneoxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer. 2003;107:381-6.
44. Liu Y, Zhang D. The NQO1 C609T polymorphism and risk of lung cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:3091-5.
45. Wang Z, Hu J, Zhong J. Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C>T polymorphism with esophageal cancer risk. DNA Cell Biol. 2012;31:560-7.
46. Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172-8.